Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

1,377 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Once-Daily Crisaborole Ointment, 2%, as a Long-Term Maintenance Treatment in Patients Aged ≥ 3 Months with Mild-to-Moderate Atopic Dermatitis: A 52-Week Clinical Study.
Eichenfield LF, Gower RG, Xu J, Alam MS, Su JC, Myers DE, Sanders P, Vlahos B, Zang C, Lan J, Werth J. Eichenfield LF, et al. Among authors: alam ms. Am J Clin Dermatol. 2023 Jul;24(4):623-635. doi: 10.1007/s40257-023-00780-w. Epub 2023 May 15. Am J Clin Dermatol. 2023. PMID: 37184828 Free PMC article. Clinical Trial.
Secukinumab in patients with moderate-to-severe hidradenitis suppurativa based on prior biologic exposure: an efficacy and safety analysis from the SUNSHINE and SUNRISE phase III trials.
Zouboulis CC, Passeron T, Pariser D, Wozniak MB, Li X, Uhlmann L, Lobach I, Martinez AL, Ravichandran S, Alarcon I, Offidani A, Alam MS, Mendes-Bastos P. Zouboulis CC, et al. Among authors: alam ms. Br J Dermatol. 2024 May 17;190(6):836-845. doi: 10.1093/bjd/ljae098. Br J Dermatol. 2024. PMID: 38470171 Clinical Trial.
Enhanced Effectiveness of Adalimumab Compared to Topical/Traditional Systemic Agents in the Treatment of Moderate to Severe Plaque Psoriasis: Results from a Canadian Observational Epidemiologic Study (COMPLETE-PS).
Lynde CW, Alam MS, Ohson K, Gagné-Henley A, Avadisian M, Vender RB. Lynde CW, et al. Among authors: alam ms. Dermatol Ther (Heidelb). 2022 Apr;12(4):921-931. doi: 10.1007/s13555-022-00703-3. Epub 2022 Mar 14. Dermatol Ther (Heidelb). 2022. PMID: 35286612 Free PMC article.
Two Phase 3 Trials of Lebrikizumab for Moderate-to-Severe Atopic Dermatitis.
Silverberg JI, Guttman-Yassky E, Thaçi D, Irvine AD, Stein Gold L, Blauvelt A, Simpson EL, Chu CY, Liu Z, Gontijo Lima R, Pillai SG, Seneschal J; ADvocate1 and ADvocate2 Investigators. Silverberg JI, et al. N Engl J Med. 2023 Mar 23;388(12):1080-1091. doi: 10.1056/NEJMoa2206714. Epub 2023 Mar 15. N Engl J Med. 2023. PMID: 36920778 Clinical Trial.
Lacrimal Canaliculitis: A Major Review.
Pal SS, Alam MS. Pal SS, et al. Among authors: alam ms. Semin Ophthalmol. 2024 May 19:1-9. doi: 10.1080/08820538.2024.2354689. Online ahead of print. Semin Ophthalmol. 2024. PMID: 38762795 Review.
Improving drinking water quality through proficiency testing-the impact of testing method and accreditation status on Escherichia coli detection by Canadian environmental testing laboratories.
Sreya M, Alam MS, Daula S, Lee C, Restelli V, Middlebrook K, Noble MA, Perrone LA. Sreya M, et al. Among authors: alam ms. Front Mol Biosci. 2024 May 1;11:1338549. doi: 10.3389/fmolb.2024.1338549. eCollection 2024. Front Mol Biosci. 2024. PMID: 38756531 Free PMC article.
1,377 results